AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26258315 — intervention group
Group type: EXPERIMENTAL
Intervention: Living donor liver transplant (LDLT)
Number of subjects: 1427
Study 26258315 — intervention group
Group type: COMPARATOR
Intervention: Deceased donor liver transplant
Number of subjects: 1427
Study 26258315 — intervention group
Group type: EXPERIMENTAL
Intervention: All recipients
Number of subjects: 1427
Study 26258656 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 242
Study 26258656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy
Number of subjects: 242
Study 26258656 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (laparoscopic and vaginal)
Number of subjects: 242
Study 26259955 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (1.0, 2.0, or 3.0 mg once daily)
Number of subjects: 18
Study 26259955 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (2.0 mg once daily) in combination with gemcitabine (1000 mg/m(2))
Number of subjects: 18
Study 26259955 — intervention group
Group type: COMPARATOR
Intervention: Trametinib monotherapy
Number of subjects: 18
Study 26259955 — intervention group
Group type: COMPARATOR
Intervention: Trametinib plus gemcitabine
Number of subjects: 18
Study 26260007 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-month walking program (one-hour sessions, three times a week)
Number of subjects: 9
Study 26260007 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 9
Study 26260306 — intervention group
Group type: EXPERIMENTAL
Intervention: HCVIDD/MA
Number of subjects: 53
Study 26261061 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and oxaliplatin
Number of subjects: 519
Study 26261238 — intervention group
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b (50 to 540 µg, administered every 2 weeks)
Number of subjects: 51
Study 26261238 — intervention group
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Number of subjects: 51
Study 26261290 — intervention group
Group type: EXPERIMENTAL
Intervention: Native T1 measurement in hypo-intense infarct core (n = 160 STEMI patients)
Number of subjects: 300
Study 26261290 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse remodelling defined as an increase in left ventricular (LV) end-diastolic volume ≥20% at 6 months
Number of subjects: 300
Study 26261290 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause death or first heart failure hospitalization
Number of subjects: 300
Study 26261849 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with nintedanib
Number of subjects: 0
Study 26261849 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 26263403 — intervention group
Group type: EXPERIMENTAL
Intervention: ETR 400 mg plus TDF/FTC 300/200 mg once daily
Number of subjects: 79
Study 26263832 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic hemorrhoids (Goligher grade I-II)
Number of subjects: 97
Study 26263832 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic hemorrhoids (Goligher grade III)
Number of subjects: 97
Study 26263832 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic hemorrhoids (Goligher grade IV)
Number of subjects: 97
Study 26263832 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 97
Study 26264378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg daily for 4 weeks of a 6-week cycle (Cohort A)
Number of subjects: 52
Study 26264378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg daily on a continuous basis (Cohort B)
Number of subjects: 52
Study 26264378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 52
Study 26264607 — intervention group
Group type: EXPERIMENTAL
Intervention: EMMA™ portable-capnometer
Number of subjects: 35
Study 26264607 — intervention group
Group type: COMPARATOR
Intervention: Side stream capnometry
Number of subjects: 35
Study 26265011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal provocation test - rapid (NPT-R)
Number of subjects: 88
Study 26265011 — intervention group
Group type: COMPARATOR
Intervention: Classic nasal provocation test (NPT)
Number of subjects: 88
Study 26265013 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 42
Study 26265130 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferential routing to approved stroke centers (ASCs)
Number of subjects: 1627
Study 26265463 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 15
Study 26265463 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nucleotide reverse transcriptase inhibitor- and integrase-strand inhibitor-based cART
Number of subjects: 15
Study 26265463 — intervention group
Group type: EXPERIMENTAL
Intervention: cART regimen not altered after HCT
Number of subjects: 15
Study 26265463 — intervention group
Group type: EXPERIMENTAL
Intervention: cART regimen altered due to complications
Number of subjects: 15
Study 26265463 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide as bridging component
Number of subjects: 15
Study 26265463 — intervention group
Group type: EXPERIMENTAL
Intervention: cART adherence
Number of subjects: 15
Study 26265463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained HIV viremia and emergence of resistance
Number of subjects: 15
Study 26265479 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR118 5.5 mg
Number of subjects: 24
Study 26265479 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR118 11.0 mg
Number of subjects: 24
Study 26265479 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR118 2.8 mg
Number of subjects: 24
Study 26265479 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR118 high dose (11.0 mg)
Number of subjects: 24
Study 26265479 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosages of PUR118
Number of subjects: 24
Study 26265479 — intervention group
Group type: COMPARATOR
Intervention: Ozone challenge
Number of subjects: 24
Study 26265699 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs10989692 (near the glutamate receptor GRIN3A locus)
Number of subjects: 2285
Study 26265699 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs10989692
Number of subjects: 2285
Study 26265699 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteonecrosis-associated glutamate receptor variants
Number of subjects: 2285
Study 26265699 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate pathway
Number of subjects: 2285
Study 26266019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 1
Study 26266019 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 1
Study 26266252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvoluntary isometric contractions (twitch and tetanic) of the quadriceps femoris muscle evoked by transcutaneous electrical muscle stimulation
Number of subjects: 12
Study 26266252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvoluntary isometric contractions (twitch)
Number of subjects: 12
Study 26266842 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal CMAP on day 8
Number of subjects: 730
Study 26266842 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal SNAP and presence of SEA on day 15
Number of subjects: 730
Study 26266842 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced CMAP on day 8
Number of subjects: 730
Study 26266842 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced CMAP among conscious/cooperative patients without weakness
Number of subjects: 730
Study 26267622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt revascularization
Number of subjects: 2285
Study 26267622 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 2285
Study 26268313 — intervention group
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV (IM prime)
Number of subjects: 42
Study 26268313 — intervention group
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV (IM boost)
Number of subjects: 42
Study 26268313 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-RSV (IM boost)
Number of subjects: 42
Study 26268514 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine (20 mg/kg, IV) prior to IVIR
Number of subjects: 26
Study 26268514 — intervention group
Group type: COMPARATOR
Intervention: IVIR (Sodium ferric gluconate, [125 mg/100 ml] for 8 weeks)
Number of subjects: 26
Study 26268782 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min rituximab infusion
Number of subjects: 50
Study 26268782 — intervention group
Group type: COMPARATOR
Intervention: Standard second dose infusion recommendation
Number of subjects: 50
Study 26268844 — intervention group
Group type: COMPARATOR
Intervention: Healthy/PA cluster (n=265)
Number of subjects: 1327
Study 26268844 — intervention group
Group type: COMPARATOR
Intervention: Healthy/diet cluster (n=unknown)
Number of subjects: 1327
Study 26268844 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy cluster (n=677)
Number of subjects: 1327
Study 26269220 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV-containing ARV regimens
Number of subjects: 12780
Study 26269220 — intervention group
Group type: COMPARATOR
Intervention: non-ZDV ARV regimens
Number of subjects: 12780
Study 26269238 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PUFA intake
Number of subjects: 311
Study 26269238 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ratio of PUFAs to SFAs
Number of subjects: 311
Study 26269238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intakes of n-3 PUFAs
Number of subjects: 311
Study 26269238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intakes of n-6 PUFAs
Number of subjects: 311
Study 26269238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of n-6 to n-3 PUFAs
Number of subjects: 311
Study 26269363 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration status measured through urinary osmolality (Uosm)
Number of subjects: 78
Study 26269363 — intervention group
Group type: EXPERIMENTAL
Intervention: Total urine volume (Uvol)
Number of subjects: 78
Study 26269365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage consumption (≥1 serving per day)
Number of subjects: 240508
Study 26269365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage consumption (dose-response analysis)
Number of subjects: 240508
Study 26269366 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated total dietary fiber intake
Number of subjects: 57774
Study 26269367 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal folate intake
Number of subjects: 368
Study 26269367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood folate concentration
Number of subjects: 368
Study 26269367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal MTHFR 677TT genotype
Number of subjects: 368
Study 26269367 — intervention group
Group type: EXPERIMENTAL
Intervention: UMFA detection
Number of subjects: 368
Study 26270946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist care intervention
Number of subjects: 100
Study 26270946 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 100
Study 26271642 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity (measured by adult EoE activity index)
Number of subjects: 98
Study 26271642 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic findings
Number of subjects: 98
Study 26271642 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological findings
Number of subjects: 98
Study 26271642 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity, endoscopic and histological findings combined
Number of subjects: 98
Study 26271642 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity
Number of subjects: 98
Study 26271944 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily) with nevirapine (400 mg once daily) and abacavir/lamivudine (600/300 mg once daily)
Number of subjects: 10
Study 26272346 — intervention group
Group type: EXPERIMENTAL
Intervention: Programme cantonal Diabète (PcD)
Number of subjects: 0
Study 26272385 — intervention group
Group type: EXPERIMENTAL
Intervention: CoaguChek POCT
Number of subjects: 60
Study 26272385 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based coagulation assays (prothrombin time, activated partial thromboplastin time, anti-Xa test, Hemoclot)
Number of subjects: 60
Study 26272656 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs at the PITX2 locus (rs6843082_G)
Number of subjects: 1068
Study 26272656 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs at the PITX2 locus (rs2200733_T)
Number of subjects: 1068
Study 26272656 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs at the ZFHX3 locus (rs2106261_A)
Number of subjects: 1068
Study 26272656 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs at the KCNN3 locus (rs13376333_T)
Number of subjects: 1068
Study 26272656 — intervention group
Group type: EXPERIMENTAL
Intervention: Top AF-associated SNPs
Number of subjects: 1068
Study 26272693 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-MPH
Number of subjects: 255
Study 26272693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 26272693 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 255
Study 26273092 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 7046
Study 26273092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7046
Study 26274928 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE
Number of subjects: 60
Study 26274928 — intervention group
Group type: EXPERIMENTAL
Intervention: HMGB1
Number of subjects: 60
Study 26274928 — intervention group
Group type: EXPERIMENTAL
Intervention: S100A12
Number of subjects: 60
Study 26274928 — intervention group
Group type: COMPARATOR
Intervention: esRAGE
Number of subjects: 60
Study 26274928 — intervention group
Group type: COMPARATOR
Intervention: AGEs
Number of subjects: 60
Study 26274928 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE, esRAGE, S100A12, AGEs
Number of subjects: 60
Study 26274928 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE, HMGB1, S100A12
Number of subjects: 60
Study 26275071 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 600
Study 26275228 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1 (genetic testing for Fabry disease)
Number of subjects: 35
Study 26275228 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2 (stent retrievers effectiveness evaluation)
Number of subjects: 35
Study 26275293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 34
Study 26275339 — intervention group
Group type: EXPERIMENTAL
Intervention: HA DNA-IIV3
Number of subjects: 111
Study 26275339 — intervention group
Group type: COMPARATOR
Intervention: PBS-IIV3
Number of subjects: 111
Study 26275339 — intervention group
Group type: COMPARATOR
Intervention: IIV3-IIV3
Number of subjects: 111
Study 26275521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hemodynamic monitoring (heart rate, mean arterial pressure, central venous pressure, cardiac index)
Number of subjects: 40
Study 26275521 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NGAL at the conclusion of surgery
Number of subjects: 40
Study 26275521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (PTX3, IL1-RA, MCP, ST-2, IL-10)
Number of subjects: 40
Study 26277428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Manager (DCM) curriculum
Number of subjects: 38
Study 26277485 — intervention group
Group type: COMPARATOR
Intervention: Upper trapezius deformation during scapular elevation (superficial section)
Number of subjects: 36
Study 26277485 — intervention group
Group type: COMPARATOR
Intervention: Upper trapezius deformation after loaded arm abduction
Number of subjects: 36
Study 26277485 — intervention group
Group type: COMPARATOR
Intervention: Engagement of deep section of upper trapezius during scapular elevation task
Number of subjects: 36
Study 26278063 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro
Number of subjects: 0
Study 26278063 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 26278654 — intervention group
Group type: EXPERIMENTAL
Intervention: PC needle (novel reverse bevel needle)
Number of subjects: 75
Study 26278654 — intervention group
Group type: COMPARATOR
Intervention: QC needle (19-gauge Tru-cut biopsy needle)
Number of subjects: 75
Study 26279673 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Abdomen procedures
Number of subjects: 0
Study 26279682 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses only (FOO)
Number of subjects: 60
Study 26279682 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses and eccentric exercise (FOE)
Number of subjects: 60
Study 26279682 — intervention group
Group type: COMPARATOR
Intervention: Sham foot orthoses only (FOS)
Number of subjects: 60
Study 26279682 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (FOO, FOE, FOS)
Number of subjects: 60
Study 26280080 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimaxillary orthognathic surgery
Number of subjects: 53
Study 26280447 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (Valsartan/Sacubitril)
Number of subjects: 0
Study 26280447 — intervention group
Group type: COMPARATOR
Intervention: Current medications (ACE inhibitors or angiotensin receptor antagonists)
Number of subjects: 0
Study 26281907 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg/day for 21 days
Number of subjects: 53
Study 26282191 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD generator replacement
Number of subjects: 800
Study 26282537 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic methods (microscopic techniques, rapid diagnostic tests, stool culture, polymerase chain reaction) for detecting bacterial and parasitic pathogens.
Number of subjects: 2000
Study 26282537 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical treatment offered to all infected participants.
Number of subjects: 2000
Study 26282537 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of patient-centred clinical algorithms.
Number of subjects: 2000
Study 26282537 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of different diagnostic methods.
Number of subjects: 2000
Study 26282634 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of methotrexate and cytarabine followed by R-HDS (cyclophosphamide, cytarabine, and etoposide) supported by autologous stem-cell transplantation (ASCT). Treatment included eight doses of rituximab and four doses of intrathecal liposomal cytarabine.
Number of subjects: 38
Study 26283632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (Tasigna™)
Number of subjects: 10
Study 26283670 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1.5 g for 5 days)
Number of subjects: 90
Study 26283670 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single oral dose)
Number of subjects: 90
Study 26283670 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 90
Study 26283670 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 90
Study 26283709 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 m gait speed (4MGS) measured at hospital discharge
Number of subjects: 213
Study 26283709 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 m gait speed (4MGS) quartile Q1 (slowest)
Number of subjects: 213
Study 26283709 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 m gait speed (4MGS) quartile Q1 (slowest) in patients aged 65 or over
Number of subjects: 213
Study 26283709 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model incorporating 4MGS and other factors
Number of subjects: 213
Study 26283710 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 3464
Study 26284164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempo-pace synchronized audio-devices with personalized music playlists + usual-care
Number of subjects: 34
Study 26284164 — intervention group
Group type: COMPARATOR
Intervention: No music usual-care control
Number of subjects: 34
Study 26284168 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners (LDR, SDR)
Number of subjects: 445
Study 26284168 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners (LDR)
Number of subjects: 445
Study 26284168 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimmers (SDS, LDS)
Number of subjects: 445
Study 26284689 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message prompts to a mobile survey assessing activity, self-worth, and self-efficacy
Number of subjects: 9
Study 26284689 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn accelerometer
Number of subjects: 9
Study 26284689 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant feedback on survey usability
Number of subjects: 9
Study 26284932 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (osmotic-release oral system)
Number of subjects: 25
Study 26284932 — intervention group
Group type: COMPARATOR
Intervention: Non-medicated respondents
Number of subjects: 25
Study 26284932 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents (medicated)
Number of subjects: 25
Study 26285132 — intervention group
Group type: EXPERIMENTAL
Intervention: GTF2I allelic variations (specifically the single-nucleotide polymorphism rs2527367)
Number of subjects: 260
Study 26285741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (1 MAC)
Number of subjects: 133
Study 26285768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (120 mg PO twice daily) and bortezomib (1.3 mg/m2 IV on specified days) per 6-week cycles
Number of subjects: 42
Study 26286026 — intervention group
Group type: EXPERIMENTAL
Intervention: Areca nut (AN) chewing
Number of subjects: 2700
Study 26286255 — intervention group
Group type: EXPERIMENTAL
Intervention: Early risk-reducing salpingectomy (RRS) with delayed oophorectomy (RRO)
Number of subjects: 0
Study 26286255 — intervention group
Group type: COMPARATOR
Intervention: Standard risk-reducing salpingo-oophorectomy (RRSO)
Number of subjects: 0
Study 26286385 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back Screening Tool (SBST)
Number of subjects: 53
Study 26286385 — intervention group
Group type: COMPARATOR
Intervention: Physiologic measures (maximal voluntary contraction)
Number of subjects: 53